Zimmer Biomet Holdings
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
- Total institutional ownership rose 0.4 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 101.20% +0.42pp
- Institutions
- 1,124 -3
- As of
- 2026/Q4 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 36 buys · 8 sells
| Name | Role | Stake |
|---|---|---|
| Ivan Tornos | Chairperson & CEO | 0.04% |
| Suketu Upadhyay | Former CFO and Executive VP of Finance, Operations & Supply Chain | 0.04% |
| Chad Phipps | Senior VP, Chief Legal & Corporate Affairs Officer and Secretary | 0.03% |
| Wilfred van Zuilen | Group President of Europe, Middle East & Africa | 0.02% |
| Sang Yi | Former President of Asia Pacific | 0.01% |
| Mark Bezjak | Former President of Americas | 0.01% |
| Rachel Ellingson | Former Senior Vice President & Chief Strategy Officer | 0.01% |
| Lori Winkler | Chief Human Resources Officer | 0.01% |
| Brian Hatcher | President, Recon, S.E.T., CMFT, Neuro and Biosurgery | 0.00% |
| Betsy Bernard | Independent Director | 0.00% |
| Paul Stellato | Interim CFO, VP, Controller & Chief Accounting Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Brian Hatcher | President, Recon, S.E.T., CMFT, Neuro and Biosurgery | Initial Statement of Beneficial | 0 | -- |
| 2026-09-30 | Gary Campbell | President of Americas | Derivative Exercise and Sale | -1,412 | $88.42 |
| 2026-09-30 | Gary Campbell | President of Americas | Derivative Exercise and Retained | +2,174 | -- |
| 2026-09-30 | Gary Campbell | President of Americas | Initial Statement of Beneficial | 0 | -- |
| 2026-09-29 | Robert Hagemann | Independent Director | Other Derivative Acquisition | +306 | $89.85 |
| 2026-09-29 | Arthur Higgins | Independent Director | Other Derivative Acquisition | +306 | $89.85 |
| 2026-09-29 | Louis Shapiro | Independent Director | Other Derivative Acquisition | +153 | $89.85 |
| 2026-09-29 | Maria Hilado | Independent Director | Other Derivative Acquisition | +375 | $89.85 |
| 2026-09-29 | Michael Farrell | Lead Independent Director | Other Derivative Acquisition | +417 | $89.85 |
| 2026-09-29 | Devdatt Kurdikar | Independent Director | Other Derivative Acquisition | +173 | $89.85 |
| 2026-09-29 | Sreelakshmi Kolli | Independent Director | Other Derivative Acquisition | +173 | $89.85 |
| 2026-09-10 | Kevin Thornal | Former Group President of Global Businesses & Americas | Open Market Disposition | -5,691 | $92.95 |
| 2026-09-03 | Chad Phipps | Senior VP, Chief Legal & Corporate Affairs Officer and Secretary | Open Market Disposition | -3,000 | $98.35 |
| 2026-08-02 | Chintan Desai | President Asia Pacific Region | Other Derivative Acquisition | +10,168 | -- |
| 2026-07-31 | Kevin Thornal | Former Group President of Global Businesses & Americas | Derivative Exercise and Sale | -4,266 | $92.68 |
| 2026-07-31 | Kevin Thornal | Former Group President of Global Businesses & Americas | Derivative Exercise and Retained | +5,691 | -- |
| 2026-07-15 | Suketu Upadhyay | Former CFO and Executive VP of Finance, Operations & Supply Chain | Intent to Sell (Form 144) | -7,668 | $92.86 |
| 2026-06-29 | Robert Hagemann | Independent Director | Other Derivative Acquisition | +317 | $86.65 |
| 2026-06-29 | Arthur Higgins | Independent Director | Other Derivative Acquisition | +317 | $86.65 |
| 2026-06-29 | Louis Shapiro | Independent Director | Other Derivative Acquisition | +158 | $86.65 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Zimmer Biomet Holdings discussion 0 comments